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ABSTRACT

Cytotoxic Effects of Ruthenium Compounds on Human Cancer Cell Lines
by
Katie Beth Brown

Chemotherapy is the most common cancer treatment. Traditionally, platinum-based
drugs are used in chemotherapy. More recently, researchers have focused on ruthenium
based compounds as a substitute for the platinum compounds. Ruthenium-based
compounds appear to be less toxic to healthy cells than traditional platinum-based
compounds. In this study, 7 ruthenium-based compounds were tested on HT-29 (colon)
and MCF-7 (breast) human cancer cell lines with the specific aim of determining whether
or not any of the ruthenium-based compounds exhibited cytotoxic properties. In addition,
levels of vascular endothelial growth factor (VEGF) production were tested in supernate
from the cancer cells treated with various ruthenium-based compounds to determine
whether or not the ruthenium-based compounds had an effect their VEGF production.
Our results indicate that none of the ruthenium based compounds tested had a cytotoxic
effect on the cancer cell lines; however, some of the compounds did exhibit inhibition of
cell growth. Results further indicate an initial decrease in VEGF production in the cell
lines treated with the ruthenium compounds but that this effect was compound-cell line
specific.
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CHAPTER 1
INTRODUCTION
According to the National Cancer Institute, nearly 1.4 million men and women in
United States are diagnosed with cancer each year. In 2006, approximately 600,000 men
and women in the United States died from cancer of all varieties. The median age of
diagnosis is 67. Approximately 41% of people born today in the United States will be
diagnosed with cancer at some point in their lifetime (Ries et al., 2007).
The diagnosis of cancer was not well comprehended until the late 19th century.
However, there is evidence that cancer affected animals well before humans inhabited
earth. The remains of a Cretaceous dinosaur and a Pleistocene cave bear were
determined to have tumors in their vertebrae (Barton-Burke & Wilkes, 2006). There is
documentation of cancer and tumors in humans dating as far back as the ancient
Egyptians. Malignant neoplasms, uncontrolled growths of abnormal tissue, have been
discovered in Egyptian mummies over 5000 years old (Barton-Burke & Wilkes).
References to benign and malignant tumors have been found on papyrus scrolls along
with references to different medicines and treatments used on the tumors, one such
treatment being Castor oil. Hippocrates, dubbed the “Father of Medicine,” and Galen,
two prominent physicians of early Rome and Greece, helped revolutionize the way
medicine was viewed. Disease, which was previously viewed as a mystical or
supernatural occurrence, became regarded as a naturally occurring physical process.
Cancer became a recognized diagnosis in the time of Hippocrates, who originally gave it
the name karkinos or karkinoma, which are Greek words for “crab.” It was named as
such because Hippocrates was reminded of a crustacean when looking at the hard center
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and spiny projections on the tumors (Chemical Heritage Foundation, 2001). Galen is
credited for being one of the earliest physicians to surgically remove tumors; however,
Galen took the stance that, in general, cancer was better left untreated. In the Middle
Ages all diseases were considered part of four Greek bodily fluids: blood, phlegm, yellow
bile, and black bile. Cancer was considered excess black bile and only curable if caught
in the very early stages. During the Renaissance, doctors based medicine more on direct
observation. Ambroise Pare′, the best-known surgeon of the era, recommended removal
of tumors by surgery but only when the cancer could be completely removed. Although
medicine advanced during this era, cancer was still believed to be the result of excess
black bile and primarily incurable. In addition, different arsenic pastes were used in
cancer treatment during this time period (Chemical Heritage Foundation). Although the
paste had very little systematic benefit, it did have a caustic effect on tumors and it
appeared that the arsenic paste did have an “antitumor” effect on the tumor itself.
Because of the apparent antitumor effect, the arsenic pastes were used as a form of cancer
treatment until 1865 when improvements in therapy were made (Barton-Burke &
Wilkes). The 1600s brought about technology such as the microscope and the telescope,
which allowed for new scientific discoveries. It was during this time that William
Harvey discredited the humoral theory of disease, the concept that an imbalance of
special fluids in the body resulted in diseases. Harvey, a well-respected medical leader in
the scientific community and physician to King Charles I of England, did this by studying
the heart and describing the continuous circulation of the blood (Weigand, 2008). Once
the idea that black bile resulted in cancer was laid to rest, cancer could be studied using
innovative ideas and new techniques. During this time scientist Robert Hooke described
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the cell and Italian physician Gaspare Aselli discovered lymphatic vessels.
Abnormalities in the lymph system were researched as the possible cause of cancer.
Although anesthesia and antiseptics were not in use during this time, mastectomies were
performed in patients with breast cancer and in many instances the lymph nodes of cancer
patients were removed as well (Chemical Heritage Foundation). In the middle 1700s,
oncology, the study of cancer, was made a specialized field of scientific study. The role
that environmental factors played in the development of cancer came into question along
with the safety of working around carcinogenic agents like chimney soot. The 19th
century brought many dramatic developments in science and several advancements in
technology. Due to autopsies performed by physicians Giovanni Margagni and Matthew
Baillie, several cancers such as cancers of the breast, stomach, rectum, and pancreas were
described in great detail. Advances in microscopy allowed scientists to differentiate
between cancerous and normal cells and to study cellular activity. It was also during this
time period that researchers in France and Italy collected the first cancer statistics. The
early 1900s welcomed in advanced cell research. The discovery of chemical carcinogens
such as herbicides and pesticides brought more focus to the study of cancer. It was also
during this time that chemotherapy, the treatment of cancer with anti-cancer drugs, was
developed (Chemical Heritage Foundation). In 1937, Congress passed the National
Cancer Institute Act, which designated yearly funding for cancer research (Hektoen,
1938). In 1939, the National Cancer Institute was formed by merging of the Office of
Cancer Investigations at Harvard University and the National Institutes of Health’s
pharmacology division. During this time the “smoking-cancer link” was initiated
(Chemical Heritage Foundation). In 1955, Congress made funds available for a National
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Chemotherapy program that allowed for the testing of different chemical compounds on
cancer. It was during this time that the link between smoking and cancer was deemed
probable. In 1964, the U.S. Surgeon General Luther L. Terry reported that lung cancer
was indeed linked to smoking (Chemical Heritage Foundation). In 1971, Congress
passed the National Cancer Act. This legislation declared that the incidence of cancer is
rapidly increasing and is a major health concern in the United States, that cancer is the
leading cause of death in the United States, and that the purpose of the Act was to
“enlarge the authorities of the National Institute of Cancer and the National Institutes of
Health in order to advance the national effort against cancer” (Library of Congress,
1971). In the mid-late 1900s, oncogenes such as src were discovered (Chemical Heritage
Foundation). Oncogenes are genes that cause the transformation of normal cells into
cancerous cells, especially a viral gene that transforms a host cell into a tumor cell
(Oncogene, 2006).
Cancer research has come a long way in the past couple of decades; however,
there is much to be learned about these quickly dividing cells that are capable of mutation
and are very harmful to healthy cells in the body. Cancer research remains a fast-pace
field with much knowledge to be acquired and a rewarding experience to be gained with
every advancement made.
Cancer Treatment and Chemotherapy
There are three main types of treatment for cancer: surgery, radiation therapy, and
chemotherapy. Chemotherapy, our main area of interest, is the treatment of cancer with
anticancer drugs and is fairly effective when cancer is caught in the early stages (The
Royal Marsden NHS Foundation Trust, 2007). Paul Ehrlich, the Director at the Royal
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Institute of Experimental Therapy in Frankfurt, Germany, is credited as being one of the
main founders of chemotherapy due to his discovery of the drug Salvarsan in 1907.
Salvarsan was used for the treatment of syphilis. Ehrlich, who was already well-known
for his many achievements in the field of immunology, based his work on the idea that,
“the chemical constitution of drugs used must be studied in relation to their mode of
action and their affinity for the cells of the organisms against which they were directed”
(Nobel Lectures, 1967). Ehrlich’s aim was to locate chemical substances with a high
affinity for organisms of a pathogenic nature to which they would directly travel. Ehrlich
referred to these chemical substances as “magical bullets” (Nobel Lectures). The first
chemotherapy drug tested on patients, nitrogen mustard, was based on a poisonous gas
(Cancer Research UK, 2007). The first documented use of chemotherapy as a cancer
treatment was in 1942 with the use of nitrogen mustard to treat lymphoma (Goodman et
al., 1984). Many advancements in chemotherapy have been made over the past decades.
The most notable advancement was the discovery of platinum-based drugs to be used in
anticancer activity.
In 1965, Barnett Rosenberg was working as a biophysicist at the University of
Michigan. Rosenberg decided to test whether or not electrical currents had a part in
cellular division. This was based upon his theory that the mitotic spindles in cell division
were much like the science experiment where magnetic field lines formed when iron
shavings are scattered on paper while a magnet is underneath (Alderden, Hall, &
Hambley, 2006). To test his hypothesis, Escherichia coli (E. coli) was grown in an
ammonium chloride buffer while a current was sent through the buffer via “inert”
platinum electrodes submerged in the buffer. After a brief time period, the E. coli cells
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failed to retain their normal shape and began to appear long and filamentous. This effect
on the E. coli was found to be the result of inhibition of cellular division (Alderden, et
al.). After a thorough study, it was determined that the electrical current did not have
anything to do with the phenomenon, but rather the phenomenon was due to the
formation of platinum hydrolysis formed from the platinum electrodes in the buffer.
From here, a number of transition metal compounds were tested, but it was the platinum
salt (NH4)2[PtCl6] that was found to have the same effect of inhibition of cellular division
in a number of different gram-negative bacilli. After more research, it was determined
that the cis form of [PtCl4](NH3)2], a platinum (IV) complex, was the factor responsible
for inhibiting cellular division; however, in the trans form, the complex was found to be
ineffective (Alderden et al.).
With these results in hand, testing began to determine whether these complexes
could be used in anticancer activity. The platinum(II) complex, cis-[PtCl2](NH3)2], and
the platinum(IV) complex, cis-[PtCl4](NH3)2], were tested on 180 sarcomal tumors in
Swiss white mice. The results not only showed that the complexes exhibited a virulent
activity and were capable of reducing large dense tumors, but that the mice survived and
were healthy after testing. The most triumphant news was that after 6 months, the mice
that had been cured showed no signs of cancer. These results were enough to send
cisplatin, cis-[PtCl2](NH3)2], to clinical trials. Today, cisplatin is one of the most
successful drugs used in chemotherapy (Alderden et al., 2006).
Currently, the most commonly used chemotherapeutic drugs are platinum(II)
compounds. The Roman numeral “II” indicates that platinum is a type II metal, meaning
it can form more than one type of oxidation state (Myron, 2004). The oxidation state
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refers to the degree of oxidation an atom, ion, or molecule has. For the purpose of
simplicity, the oxidation state and number can be used interchangeably, and the oxidation
number for simple atoms or ions is equal to the ionic charge (WordNet, 2006). In
addition to cisplatin, two common platinum(II) compounds are carboplatin and
oxaliplatin (National Cancer Institute, 2007). Carboplatin appears to be less toxic to
healthy cells than cisplatin and has infrequent and less harsh side effects. The lessened
toxicity is thought to be due in part to its molecular structure, which gives it a slower
reaction time in the body. In 2002, oxaliplatin was approved in the United States to treat
advanced colorectal cancer. To date, oxaliplatin is the only platinum based compound to
display anticancer activity against colorectal cancer (Alderden et al.). While carboplatin
and oxilaplatin are both effective and less toxic to healthy cells than cisplatin, these drugs
still exhibit negative affects on healthy cells.
The main object of chemotherapy drugs is to kill cancer cells without having
harmful effects on healthy cells in the body (The Royal Marsden NHS Foundation Trust,
2007). The most commonly used chemotherapy drugs are organometallic compounds.
Organometallic compounds contain bonds between one or more metal atoms and one or
more carbon atoms of an organyl group (IUPAC Compendium of Chemical Terminology,
1997). DNA is the primary binding site of the organometallic compounds. The
backbone of the DNA is made up of four nucleotides: adenine, thymine, guanine, and
cytosine. Adenine always binds to thymine, while guanine always binds to cytosine.
Platinum binds to DNA by cross-linking, or forming bonds with, adjacent guanines
causing a class of DNA binding proteins to adhere to the DNA and is able to interact with
the nucleic acids (Bonnet & Taylor, 1989).
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Three modes of association between metal complexes and DNA are generally
distinguished: external binding, groove binding, and intercalation. External binding is
when the compound binds to the outside of the DNA helix. Groove binding is when the
compound binds in the grooves made by the double helix. Intercalation is when the
compound binds between the base pairs of nucleotides, which form the double helix. The
conditions of binding depend on the nature of the metal and surrounding donor groups
(Miller, Taylor, & Basch, 1985).
Problems have been encountered with many of the currently used platinum based
compounds, specifically cisplatin. Some of these problems include developed drug
resistance by the tumor cells, which can later cause a relapse, toxic effects of the
compounds on healthy tissue, inadequate tissue targeting, and impaired transport-uptake
of the compound by the tumor cells (Anderson, Herman, & Rochon, 2007). Additionally,
cisplatin can only treat a limited range of cancers, such as testicular, ovarian, bladder,
head and neck tumors (Anderson et al., 2007). One of the primary aims of researchers in
this field is to synthesize metal-based drugs with unique DNA binding activities capable
of overcoming the problem of cellular resistance to cisplatin and of limited activity
against common tumors, such as gastrointestinal and breast cancers (Miller et al.).
In addition to problems such as drug resistance, another major problem with
platinum-based drugs is that they have several side effects including: severe nausea,
vomiting, loss of appetite and taste, difficulty in eating, diarrhea, and anorexia (National
Cancer Institute, 2007). Due to the traumatic side effects of platinum-based compounds,
a great effort has been made to find new metals, to substitute in place of platinum
(Anderson et al., 2007). Transition metals should work well because of their many
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oxidative states and similar properties to platinum. The transition metals that have shown
promise are titanium, vanadium, and ruthenium. Of these three, ruthenium seems to be
the most promising because it demonstrates greater resistance to hydrolysis than other
traditional platinum complexes and demonstrates a more selective action on tumors
(Anderson et al.). It is believed that metal-based compounds that do not contain
platinum, such as ruthenium based compounds, will have different biodistributions,
different mechanisms of action, and be less toxic to healthy tissue due to the difference in
oxidative properties (Ravera, Baracco, Cassino, Zanello, & Osella, 2004).
The absence of direct cell toxicity, rather than being a limitation to their use might
be mandatory for low side effects on healthy tissues, a depressing common bias of
any pharmacological approach to cancer treatment (Capozzi et al., 1998).
Ruthenium. Ruthenium is a rare transition metal of the platinum group.
Ruthenium(III) complexes are the most recent group of compounds to be studied. The
metal-DNA binding of the ruthenium complexes to DNA is a function of size, shape, and
hydrophobic characteristics of the complex as determined by the chemical structures of
the ligands of the complex. These complexes have characteristic sulfoxide and nitrogendonor ligands, a smaller molecule that specifically binds to a larger molecule, and have
been reported to exhibit antimetastatic properties (Genentech, Inc., 2007). The two key
characteristics of ruthenium(III) complexes are their exceptional antimetastatic behavior
and the exhibition of antitumor activity.
The imidazolium trans-tetrachloro(dimethylsulfoxide)imidazoleruthenate(m) is an
anionic complex known as NAMI-A, chemical formula [ImH][Ru(III)Cl4(DMSO)(Im)].
It is the first ruthenium-based compound to complete phase I clinical trials (Bacac, 2002).
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Of the ruthenium complexes tested, NAMI-A has shown the most promise as an
anticancer agent because it inhibits metastasis formation and growth while being devoid
of severe cytotoxic effects to healthy cells. Also, it does not appear to modify cell growth
in healthy tissue (Ravera et al., 2004).
Although direct toxicity to the tumor itself is a key factor of a chemotherapeutic
drug, antimetastatic properties are equally as important. Metastasis occurs as tumor cells
spread from the primary tumor site to a secondary site, which is in at another part of the
body (Bashyam, 2002). The dominant cause of a poor clinical outcome in cancer patients
is the progression of tumors from a benign state with limited growth to an invasive state
with tumor metastasis (Sava et al., 2004).
A possible mechanism for NAMI-A’s activity on metastasis is not the
conventional cytotoxic mechanism, but it appears that NAMI-A promotes metastatic cell
changes by way of a phenotype not as invasive or malignant (Bacac, 2002). This
mechanism of action was investigated using a new murine metastatic cell line (metGM),
which was previously isolated, stabilized, and fully characterized. The metGM cells
present two phenotypically different subpopulations, each with an opposite response to
NAMI-A. The metGM cell line was used as an in vitro model to study the metastatic
effects of NAMI-A on metastatic cells. It was found that NAMI-A is not suppressive for
the host immune system, induces the metabolic activation of resting lymphocytes, and
maintains induced activation of lymphocytes. This suggests that NAMI-A uses a
selective and different mechanism of action than traditional platinum-based drugs in
dealing with metastatic and host immune cells (Bacac, 2002). Possible explanations are
the significant increase of tumor cells in the G2/M phase where the cells are growing and
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getting ready to divide, although this is not a common effect for all tumor cell lines
(Bergamo et al., 1998). In vitro, NAMI-A shows temporary cell cycle arrest of tumor
cells in the premitotic G2/M phase, while cisplatin appeared to cause a progressive
interruption in the different phases of the cell cycle in a dose-dependent manner
(Bergamo et al., 1998). It is hypothesized that NAMI-A shows temporary cell cycle
arrest of tumor cells in the premitotic G2/M phase by tying up the DNA so that the DNA
cannot replicate (Sava et al., 2003). This gives insight to new mechanisms by which
other ruthenium-based compounds with similar chemical properties to NAMI-A may
interact with DNA to result in antimetastatic properties.
Ruthenium-based compounds are also good antitumor agents compared to
cisplatin. Testing was done in vitro on TLX5 lymphoma cells in order to compare
ruthenium compounds NAMI-A, Na[trans-RuCl4(TMSO)Ind] (TIND), and Na[transRuCl4(TMSO)Iq] (TEQU) with cisplatin (Capozzi et al., 1998). Cell cycle modifications
were observed in the lymphoma cells and the protein content was measured. The pattern
of effects varied among the ruthenium compounds. TEQU and cisplatin appeared to have
the similar cytotoxicity in a dose-dependent manner and DNA fragmentation, while
TIND had a small increase in S and G2M populations when the tumor cells were exposed
in a time-dependent manner. NAMI-A appeared to have no effect on direct tumor
cytotoxicity but was found to have strong, antimetastatic properties (Capozzi et al.,
1998). In fact, NAMI-A appears to be a unique antitumor agent:
It [NAMI-A] is as active of, or even more active than cisplatin in several
experimental conditions but differs from this compound for the low or absent
side-effects detectable at active dosages (Capozzi et al., 1998).
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While the mechanism of action of NAMI-A is still extensively unknown, it is
common knowledge that ruthenium(III) complexes are more inactive than their analogous
ruthenium(II) derivatives. An “activation by reduction” mechanism has been suggested
to help explain the biological activity of all chloro-amino ruthenium derivatives (Ravera,
et al., 2004). Because the amount of oxygen is less and the pH is lower at tumor sites, the
“activation by reduction” mechanism of ruthenium causes it to be extremely selective as
the metal complexes may aggregate in the oxygen-lacking environment (Anderson et al.,
2007).
Once the “activation by reduction” has taken place in a ruthenium(III) complex,
or hydrolysis of at least one chloride has occurred, the complex has the capability to bind
to DNA or another very important plasma protein known as transferrin (Alessio et al.,
2000). Transferrin is a blood plasma protein that is responsible for iron transportation in
the body, specifically for expediting transport into cells (Centers for Disease Control and
Prevention, 2007). Cancer cells have a high affinity binding to transferrin (Chan &
Gerhardt, 1992). Iron is required by all living systems since it is an essential component
of many important enzymes. Iron is taken up into cells by way of the transferrin (Tf)transferrin receptor (TR) complex. Once free ferric iron binds to apotransferrin, the ironTf complex binds to the cell surface transferrin receptor. The iron-Tf-TR complexes are
then internalized in coated vesicles by way of receptor-mediated endocytosis. Once
inside the endosome, the iron is released from transferrin and is taken to its site of use.
The mechanism of translocation of the endosome is not yet known (Chan & Gerhardt).
Cancer cells have a high number of transferrin receptors on their cell surface. Because of
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this, it is thought that NAMI-A and other ruthenium complexes are taken up into the cell
via this method.
Role of VEGF. Tumor growth and metastasis survival are strongly dependent on
nourishment provided by the bloodstream. Because cancer cells multiply very rapidly,
they require a high blood flow to provide nutrients for this cell division. Thus, the ability
to produce an endless blood supply is a valuable asset for tumors. Tumors ensure this
continual blood supply by forming new capillaries from preexisting blood vessels, a
process known as angiogenesis (Quantikine Human VEGF Immunoassay, 2006).
Angiogenesis is regulated by vascular endothelial growth factor (VEGF).
VEGF is a heparin-binding glycoprotein. It is homodimeric and is approximately
34 – 42 kDa in size. There are several isoforms of VEGF, including VEGF-A, VEGF-B,
VEGF-C, VEGF-D, and PIGF. VEGF-A, the most common variant simply referred to as
VEGF, was the interest of our study as it is the signaling protein for angiogenesis. VEGF
works by stimulating cellular responses by binding to tyrosine kinase receptors on the
cell surface, causing them to dimerize and become activated through
transphosphorylation (Quantikine Human VEGF Immunoassay, 2006). VEGF is
produced in nearly all cancer cell lines (Rad et al., 2007).
There are two different methods of blood vessel formation in embryos:
vasculogenesis and angiogenesis. In angiogenesis, new blood vessels are formed from
preexisting blood vessels (Ferrera & Alitalo, 1999). During embryonic development a
primary vascular plexus is formed. Later the endothelial channels are remodeled and a
hierarchy of large and small blood vessels is formed. New capillaries form by sprouting
or splitting from their original vessels. This process is known as intussusception. Wang,
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Tu, Wang, and Zhou, (2006) reiterate the fact that angiogenesis is necessary for tumor
growth and promotes the progression and metastasis of tumors. It is known that VEGF is
produced for the stimulation of tumor vascularization. VEGF has been observed in
adenocarcinomas (Wang, Tu, et al., 2006). Angiogenesis is necessary in adult women for
the female reproductive cycle. It also is necessary for repair, remodeling, and
regeneration of tissues. The two classifications of known endothelial growth factors are
VEGF and angiopoietin. Of the two, VEGF is most important for the development and
differentiation of the vascular system. If even one VEGF allele is lost, the result is
embryonic lethality. If one of the heparin binding isoforms of VEGF is selectively
inactivated still leaving one functional isoform (VEGF120), the cardiovascular system will
not be able to form properly and the result will be myocardial ischemia, perinatal, or
early postnatal death (Ferrera & Alitalo). VEGF production is significantly increased in
most cancer cell lines thus ensuring a continuous blood supply to the cancer cells. This
results in an increased microvascular density (Ferrera & Alitalo). In vitro, VEGF has
potent mitogenic activities specific for endothelial cells and in vivo, VEGF can induce
angiogenesis as well as increase vascular permeability.
VEGF expression can be regulated in multiple ways. Well-known regulators of
VEGF expression are peroxisome proliferator-activated receptors (PPARs). VEGF
expression is also regulated by growth factors, cytokines, oncogenes, and tumorsuppressor genes (Wang, Wang, et al., 2006).
VEGF is expressed physiologically in different tissues. Tissue oxygen tension is
the balance between oxygen supply and demand. When more oxygen is needed, VEGF
production is induced. Therefore, tissue oxygen tension is a regulator of VEGF
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production. Low oxygen tension occurs in solid tumors when the oxygen supply and
oxygen consumption become imbalanced (Nakayama et al., 2006). When exposed to
hypoxia, VEGF expression is induced by increased transcription and stabilization of
mRNA (Pellizzaro, Coradini, & Daidone, 2002). The principle inducer of VEGF
synthesis is hypoxia-inducible factor (HIF-1), which binds to elements that are responsive
in the promoter region of specific genes in order to increase the transcription of the gene
(Nakayama et al.).
HIF-1 plays a major role in angiogenesis and tumor growth. HIF-1 is a
transcription factor that is heterodimeric and consists of HIF-1α and HIF-1β subunits
(Pellizzaro et al., 2002). In vivo, the inhibition of HIF-1α leads to the reduced tumor size
while the expression of HIF-1α causes a growth in tumor size. VEGF protein expression
is mediated by phosphoinositide 3-kinase (PI3K) at the transcriptional level through the
expression of HIF-1α in human ovarian cancer cells (Skinner, Zheng, Fang, Agani, &
Jiang, 2004). PI3K inhibition by LY294002 decreased the transcriptional activation of
VEGF while the forced expression of AKT, a cancer gene regulatory subunit, completely
reversed the inhibitory effect. This is another example of how VEGF is regulated by
HIF-1α and demonstrates another method by which blocking pathways can inhibit VEGF
expression (Skinner et al., 2004).
The short-chain fatty acid sodium butyrate (NaB) is present in the human colon.
It is able to modulate many cellular processes including cell cycle arrest, differentiation,
and apoptosis in colorectal cancer cells. Pellizzaro et al. (2002) examined NaB to see
whether it could regulate the levels of angiogenesis-related factors, specifically VEGF
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and HIF-1α, in HT29 cells, a colon cancer cell line. NaB showed a dose-dependent
decrease in VEGF and a dose-dependent increase in HIF-1α mRNA (Pellizzaro et al.).
Using two different shRNA expression vectors, expression of VEGF was
inhibited in a line of colorectal adenocarcinoma cells, HT-29, by reducing the
transcription levels of VEGF mRNA, which reduced VEGF protein levels (Li et al.,
2007). First, this demonstrates that HT-29 cells do in fact produce VEGF. Second, if the
ruthenium compounds being tested in Forsman’s lab at East Tennessee State University
were able to target RNA and interfere with the VEGF gene, VEGF production would stop
or be reduced, thereby cutting off the blood supply to the cancer cells.
VEGF receptors are expressed in human colorectal carcinoma (CRC) cell lines as
shown by analysis of real-time quantitative PCR (Wang, Tu, et al., 2006). Different cell
lines exhibit different VEGF receptors (Wang, Tu, et al.). It is possible that the
ruthenium compounds being tested, such as NAMI-A, bind to certain receptors, which
could inhibit VEGF expression in cancer cells, thereby inhibiting cancer cell growth
(Wang, Tu, et al.).
While there are multiple isoforms of VEGF, VEGF-A is a positive regulator for
angiogenesis. Generally, VEGF-A binds two high affinity receptor tyrosine kinases
(RTKs), VEGFR-1 (Flt-1) and VEGFR-2 (Flt-1/KDR). VEGFR-2 is the major
intermediary of VEGF-A’s mitogenic and angiogenic signals (Nguyen et al., 2006).
Microarray analysis recently showed that VEGFR is expressed in human colon cancer
cells, HCT8/S11 (Nguyen et al.). This suggests that colon cancer cells may be targeted by
several angiogenic factors.
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VEGF functions as a mitogenic and permeability factor as well as an antiapoptotic
survival factor by initiating intracellular signaling. Thus, VEGF and VEGFR signaling
pathways are being targeted in the treatment of solid tumors. In animal models, a
VEGFR tyrosine kinase inhibitor has been shown to hinder angiogenesis and tumor
progression. Out of several models studied by Yokoi et al. (2005) many specimens
expressed several growth factors including VEGF, VEGF receptor (VEGFR), and
phosphorylated VEGFR (pVEGFR).
VEGF causes angiogenesis in human colon cancer (Ellis et al., 1998). There has
been recent evidence to suggest that regulatory factors of VEGF expression may in part
depend on signal transduction pathways mediated by c-src (Ellis et al.). In most colon
tumors and cell lines the tyrosine kinase activity of Src is activated. In subclones of
HT29 cells, Src expression and activity were decreased as a direct result of a transfected
antisense expression vector (Ellis et al.). Ellis’ group looked at whether or not VEGF
expression is decreased in the HT29 cell line as well as whether or not the reduced size
and growth rate of antisense vector-transfected cell lines in vivo may partially by the
result of reduced vascularization of tumors. Results indicate that VEGF mRNA
expression in this cell line was decreased in proportion to the decrease in Src kinase
activity (Ellis et al.).
Zhang, Wei, Xu, Wang, and Wu, (2007) looked at growth factors-cytokines and
their receptors that are known to play a role in upregulation in human tumors, specifically
colorectal carcinoma. VEGF seems to be a key cytokine upregulated in CRC. They also
noted that VEGF has a role in proliferation and migration induction of epithelial cells. In
tumors, VEGF enhances vascular permeability that allows the cancer cells to enter the
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bloodstream and possibly filtrate to places far from the original site. It is a possibility
that VEGF is a “trigger” and receptor tyrosine kinases (RTK’s) may play a role in the
regulation of VEGF expression. Many researchers are attempting to look at specific or
broad receptors that can be targeted to shut off VEGF expression (Zhang et al.).
VEGF is commonly known to promote pathogenesis of all cancer types looked at.
In breast cancer cells, it has been suggested that VEGF is able to act as an internal
autocrine (intracrine) survival factor when bound to VEGFR1 (Lee et al., 2007). This is
the first evidence of this unique survival system. Breast cancer cells express both VEGF
and VEGF receptors VEGFR1, VEGFR2, and NRP1; however, there are differing
opinions about the expression of these receptors in breast cancer. While some reports say
VEGFR1 and VEGFR2 are strongly expressed in breast cancer tissue, others disagree and
say there is a low expression of these receptors (Lee et al.). New reports have stated that
VEGF acts as an autocrine growth and survival factor, although more research is being
done to validate this claim (Lee et al.).
Colon carcinoma and other solid tumors depend upon neovascularization for
initiation, progression, and metastasis. HT-29 is a model cell line to study. Of several
angiogenetic inducers described in the HT-29 cell line as well as other colon carcinomas,
VEGF is the most important (Pellizzaro et al., 2002). VEGF plays a primary role in the
development of tumors and is associated with progression and metastasis of colon cancer.
Many VEGF isoforms have been produced through alternative exon splicing of the gene.
Of these, VEGF165 is the main form connected to the progression of colon cancer
(Pellizzaro et al.).
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Because most types of cancer cells produce VEGF, new methods are being
examined for blocking VEGF production by tumor cells (Rad et al., 2007). Scientists
have come up with several methods to block VEGF production in cancer cells. Some of
these treatments include tyrosine kinase receptor inhibitors, soluble receptors, and mAbs
against VEGF. To date, all of the above-mentioned methods have been used in clinical
trials. Although they seem to be somewhat effective in counteracting some of the
pathogenic effects of VEGF, negateve side effects such as thrombosis, bleeding,
hypertension, and proteinuria have occured. Rad et al. looked at immunizing mice using
a new method known as an “mVEGF kinoid.” The kinoid consists of a keyhole limpet
hemocyanin (KLH)-mVEGF heterocomplex. The result of the immunization with the
kinoid was that neutralizing autoantibodies to mVEGF were induced, resulting in the
inhibition of lung metastases. More tests will be run to determine whether this method
will be a suitable way to inhibit VEGF production in cancer cells (Rad et al.).
One of the major problems in the application of several newly targeted anticancer
drugs, including inhibitors of angiogenesis, is the ability to determine a biologicaltherapeutic dose that is effective. The reason for this is that the optimum therapeutic
activity of many new drugs is expressed below the maximum tolerated dose, if the dose
can be defined at all. Therefore, surrogate markers are necessary to establish optimal
dosing. In tumor-bearing mice, a rapid increases of mouse VEGF was observed within
24 hours after injections of an anti-VEGF receptor, VEGFR-2, which is a monoclonal
antibody. Similarly, an increase of human plasma VEGF was seen in tumor-bearing
mice. Plasma VEGF levels increase in a dose-dependent manner in mice when injected
with VEGFR-2 (Bocci et al., 2004).
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Currently, ruthenium complexes are being developed and tested in hopes of
reducing tumor growth and metastasis as well as ultimately interrupting or blocking
VEGF production. Once an effective therapeutic dose is determined from many newly
developed chemotherapy drugs, steps can be taken to determine whether or not an
effective way of stopping the development and spread of cancer will be found. There is
hope that one day we will gain control over cancer and be able to save many lives.
In the present study, we examined the cytotoxicity of seven ruthenium compounds
on two human cancer cell lines, HT-29 and MCF-7. Cytotoxicity can be defined as the
external cell killing by any compound causing cell death (Altweb, 2007). The
cytotoxicity was determined in human cell lines HT-29 and MCF-7 by using MTT
assays. The HT-29 and MCF-7 cell lines are of particular interest as these cell lines have
been found to be resistant to treatment with cisplatin. Therefore, it is our hope that the
ruthenium compounds tested in this study will have a cytotoxic or inhibitory effect on the
cell growth and possibly go on for further testing as potential chemotherapeutic agents.
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CHAPTER 2
MATERIALS AND METHODS
Cancer Cell Lines
The cell lines used in these studies were Human Colon Adenocarcinoma (HT-29)
and Human Breast Carcinoma (MCF-7)(cat. #’s HTB-38 and HTB-22, ATCC, Manassas,
Virginia). The HT-29 cells were originally harvested from a white female and the MCF-7
cells were originally harvested from a white male. Both of these cell lines are adherent
cell lines, which means they adhere to the surface of the container in which they are
grown.
Cell line LM929 was generously donated by Stephen Keith Chapes (Kansas State
University, Manhattan, KS). LM929 is a macrophage cell line and was used in this study
as a negative control as it does not produce VEGF.
Cell Preparation and Treatment
HT-29 cell lines were maintained by culture in McCoy’s 5A medium
supplemented with 10 % FBS and ampicillen-streptomycin at 100mg/ml and 25 mg/ml,
respectively. Passage of the cells was accomplished using the following method. To
remove cellular debris from the culture the 25 cm2 flasks (Fisher Sci, Pittsburg,
Pennsylvania) were rinsed with 3ml of sterile PBS. The cells were rinsed again with 4ml
of sterile PBS as this line of cells had a lot of cell debris and needed to be rinsed twice.
The PBS was then suctioned off. 3ml Trypsin (1X) (cat. # 25-050-Cl, Mediatech, Inc.,
Herndon, Virginia) was added to the flask. Trypsin is used to remove adherent cells from
the flask. To assist in cellular release the flask was placed in an incubator for 10 minutes
at 37°C and 5% CO2. Cells were rinsed from the flask with 4 ml McCoy’s 5A complete
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media. The resulting suspension (cells, 3 ml Trypsin, and 4 ml media) was transferred to
a 15 mL conical tube (Fisher Sci, Pittsburgh, Pennsylvania). An additional 5 mL of
complete media was added to the conical tube for a total volume of 12 mL. The
additional media was added to inhibit the Trypsin because the media contains Trypsin
inhibitor and prolonged exposure to Trypsin is harmful to the cells. The cell suspension
was centrifuged for 10 minutes at 8°C and 1000 RPM. Once centrifugation was
complete, the supernate was suctioned off and disposed of and the cell pellet was
resuspended in 6 mL complete media and returned to the culture flask and placed in the
incubator.
The MCF-7 cell line was maintained in the same manner as the HT-29 cell line
with the exception of the media used. This cell line was cultured in DMEM medium
supplemented with 10% FBS and carbenicillin/streptomycin at 100mg/ml and 25 mg/ml,
respectively.
The LM929 cell line was maintained by culture in DMEM medium supplemented
with 10% FBS and carbenicillin/streptomycin at 100mg/ml and 25 mg/ml, respectively.
Passage of the cells was accomplished using the following method. The media was
suctioned off and 3 mL Trypsin (1X) was added to the flask. After 30 seconds the
Trypsin was suctioned off, leaving the cells mildly adhered to the flask. Cells were rinsed
from the flask with 6 mL DMEM complete media. The cells were pipetted up and down
in the complete media and placed in the incubator.
Prior to starting an MTT assay, cells were moved to a Corning 75 cm2 flask
(Fisher Sci, Pittsburg, Pennsylvania) to mass produce cells. Cell lines were maintained in
the same manner as above; however, once cells were resuspended in 6 mL complete
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media, the cell suspension was divided evenly between two 75 cm2 flasks and filled with
complete media to bring the total volume of each flask to 25 mL.
Synthesis of Ruthenium Compounds
The organometallic compounds used in these studies were synthesized by Radhey
Srivastava (University of Louisiana, Lafayette) and sent to the laboratory of Allan
Forsman (East Tennessee State University, Johnson City) for use in cytotoxicity assays.
The compounds assayed are listed in Table 1.

Table 1
List of Ruthenium Compounds
________________________________________________________________
Compound Name
Molecular Formula
Molecular Weight (g/mol)
________________________________________________________________
NG2

RuCl3(TMSO)(1,10-phenanthroline)

Unknown

QL19

K[RuCl3(bpy)(SCN)]

359.64

RS216

[RuCl3(bpy)(NCOPh)]

Unknown

RS242

K[RuCl2(TMSO)(bpy)(methyl p-tolylsulfide)]

609.66

RS244

K[RuCl3(TMSO)3]

559.03

RS247

K[RuCl3(TMSO)3]

559.03

RS250

[RuCl3(TMSO)2(NO)]

445.76

Note: Structures in blue have not been established yet.
________________________________________________________________
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A brief description of compound synthesis is as follows:
Compound NG2 was made via the reaction of a molar ratio of 1:1 of
H(TMSO)]{RuCl4(TMSO)2 and phenanthroline in 95% ethanol at room temperature.
This reaction yielded a precipitate, which was named NG2.
Compound QL19 was made by dissolving mer-[RuCl3(DMSO)(bpy)] and KSCN
separately in acetone and water, respectively. The two solutions were mixed together and
heated to 80°C for 4 hours. The solvent was placed on a rotary evaporator then dried in a
vacuum. The resulting product was recrystallized in hot acetone.
Compound RS216 was made by dissolving mer-[RuCl3(DMSO)(bpy)] and
benzohydroxamic acid separately in dichloromethane. The clear benzohydroxamic acid
solution was slowly added to the mer-[RuCl3(DMSO)(bpy)]. The solution was heated at
80°C for 19 hours. The solvent was placed on a rotary evaporator then dried in a vacuum.
The solid product was recrystallized in dichloromethane and hexane.
Compound RS242 was made by dissolving a molar ratio of 1:1 of
RuCl3(TMSO)(bpy) and AgNO3 separately in acetonitrile. The AgNO3 solution was
slowly added to the RuCl3(TMSO)(bpy) solution over a 1-hour time period. AgCl
precipitated, was filtered out, and rejected. Methyl-p-tolyl sulfide was added to the
solution and stirred at room temperature over a period of several hours. This yielded a
yellow precipitate that was filtered out, washed with cold acetonitrile, and dried in a
vacuum. The reaction was carried out in a N2 atmosphere in a 1:1:1 molar ratio of the
reactants. Based on infrared (IR) spectroscopy analysis, the formula for this compound
was determined to be K[RuCl2(TMSO)(bpy)(methy-p-tolyl sulfide].
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Compound RS244 was made by adding solid potassium salt of oxalic acid to a hot
solution of cis-[RuCl2(TMSO)4] in methanol. The mixture was refluxed for 5 hours. KCl
precipitated, was filtered out, and rejected. The mixture was placed on a rotary
evaporator. This yielded a sticky yellow solid that was stirred overnight in a mixture of
acetone and diethylether. The yellow solid was filtered and dried in a vacuum.
Compound RS247 was made by adding solid potassium salt of malonic acid to a
hot solution of cis-[RuCl2(TMSO)4] in methanol. The mixture was refluxed for 2.5 hours.
KCl precipitated, was filtered out, and rejected. The volume was then reduced to
approximately 3 mL on a rotary evaporator and placed in a hood for slow evaporation.
This procedure yielded a yellow crystalline produce. The X-ray analysis of the
compound revealed the structure to be K[RuCl3(TMSO)3].
Compound RS 250 was made by dissolving a molar ratio of 1:1 of
RuCl3(TMSO)3 and benzohydroxamic acid separately in acetonitrile. The mixture was
refluxed for 4 hours. The volume was then reduced to approximately 5 mL and placed in
a freezer overnight. This procedure yielded a brown solid precipitate, which was filtered,
washed with cold acetonitrile and diethlether, and dried in a vacuum. The assumed
formula for the compound is [RuCl3(TMSO)2(NO)].
Preparation of Ruthenium Compounds
The ruthenium compounds were received in powder form. Compounds were
weighed on an electronic scale. Calculations were made to reconstitute the compounds at
a concentration of 10 mg/ml and the appropriate amount of solvent was added to each
compound. The compounds were placed on a vortex mixer to thoroughly mix and
dissolve the compounds. Within minutes, compounds QL19, RS216, RS242, RS247, and
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RS250 settled out of solution: however, the remaining liquid for each was no longer
clear, indicating that some compound had gone into solution. The tubes containing
compound were then placed in a water bath for 10 minutes at 37°C and then vortexed.
The compounds settled out once again. This procedure indicated to us that these
solutions were supersaturated. For definition purposes, the maximum amount of
compound that would go into solution will be referred to as “saturated” and the maximum
saturation concentration cannot be higher than 10 mg/ml. Compound NG2 had
previously been diluted at 10 mg/ml and was also determined to be supersaturated.
Compound RS244 was the only compound to go into solution when diluted at 10mg/ml.
Cytotoxicity Assay
For both the HT-29 and MCF-7 cell lines, 96 well microplates were seeded at 2 x
104 cells per well with a final well volume of 106 μl. 102 μl complete medium was
placed in the first three wells and 53 μl complete medium was placed in the remaining
wells across two rows for each compound tested. For accuracy, a multitip pipette was
used throughout the experiment. 4.24 μl of a saturated compound was added to each of
the first three wells for each compound tested, giving each of the first three wells a
volume of 106.24 μl. The compounds were serial diluted across 2 rows of the 96-well
plate by removing 53 μl from each of the first three wells and pipetting it into the next
triplicate of wells. This procedure was repeated across two rows in triplicate. The
remaining 53 μl from the last three wells of the dilution was discarded. Cells were added
to each well at a density of 2 x 104 cells/53 μl complete medium. Controls used in the
assay consisted of serial dilutions of HCl to establish a percent kill curve, medium only
control, cell in medium control, acetone control, acetonitrile control, dimethyl sulfoxide
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(DMSO) control, and methylene chloride control. Acetone, acetonitrile, DMSO, and
methylene chloride were necessary controls as these four were used as solvents to
dissolve some of the ruthenium compounds and it needed to be shown that the solvents
did not cause cell death or growth inhibition in either cancer cell line. Assays were
incubated for 72 hrs. at 37ْC and 5% CO2. Following the incubation period, assays were
developed using a CellQuanti-MTT cell viability assay kit (Bioassay Systems, Hayward,
CA). The assays were developed by adding 20 μl of MTT reagent to each well. The 96well microplates were then incubated for an additional 4 hours. 100 μl of solubilization
buffer was placed in each well and the plate put on a plate shaker for 1 hour to dissolve
the formazan crystals. The 96-well microplates were read on a Cary 50 plate reader
(Varian, Palo Alto, California) at 590nm using Cary WinUV software. Several assays
were read at 620nm as cited by the literature as an acceptable value; however, upon
comparison between the suggested value of 590nm and the alternate value of 620nm, a
major discrepancy was observed and tests read at 620nm were discarded and results
removed from the data. After the plates were read, a standard curve was established via
linear regression (Mathematica 7.1, Wolfram Research) using the HCl values. Next, the
percent kill (% kill) of compounds and controls tested was determined using the % kill
formula. The % kill formula is as follows: (Exp - Ctl)/(Max - Ctl) x 100 =, where Max is
acid control and Ctl is the media control. Because no % kill was observed in our assays,
percent inhibition was determined using the formula (1-A/B) x 100%. In this equation,
mean absorbance values of the treated and control wells are represented by A and B,
respectively.
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The MTT assay is a colorimetric assay that is based on the conversion of
tetrazolium salt MTT, which is a pale yellow substrate, to formazan, which is a purple
dye (Figure 1).

Figure 1. Conversion of MTT to formazan. (Wikipedia, 2006)

The assay involves a cellular reduction reaction involving two pyridine
nucleotide factors, NADH and NADPH. The reduction occurs only when mitochondrial
reductase enzymes are active, making the conversion specifically related to the number of
living cells. Because MTT is only catalyzed by living cells, it is a good way to measure
cell growth (CellQuanti-MTT Cell Viability Assay Kits, 2004). In the final incubation
period living cells produce a crystalline formazan product. When a solubilization
solution is added in the final step of the assay to dissolve the formazan product, the result
is a purple solution. The absorbance is quantified spectrophotometrically by measuring
the wavelength at 590 nm. Comparing the amount of purple formazan produced by cells
treated with the ruthenium-based compounds to the amount of formazan produced by
control cells that underwent no treatment, allows the calculation of the effectiveness of
the ruthenium-based compounds in causing cell death by using a dose-response curve
generated from the control cells (CellQuanti-MTT Cell Viability Assay Kits). The
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ruthenium compounds were further tested to see whether or not there was an effect on
VEGF production.
Vascular Endothelial Growth Factor Assay
The VEGF assays were performed using a Quantikine Human VEGF
Immunoassay (catalog number DVE00, R&D Systems, Minneapolis, Minnesota). The
assay is used to quantitatively determine the concentration of human VEGF in cell
supernates, serum, and plasma.
In preparation for the first VEGF assay, 96-well microplates were set up in the
same manner as an MTT assay and incubated for 72 hours. However, the 96-well
microplates containing HT-29 cells were seeded at different cell concentrations. Separate
microplates were seeded 5 x 103, 1 x 104, 5 x 104, 8 x 104, and 2 x 105 cells per well in
order to test which cell concentration yielded the most VEGF. Plates were incubated at
37ْC and 5% CO2. Supernate was collected for 4 consecutive days from wells treated
with compounds NG2, QL19, RS216, RS242, RS244, RS247, and RS250. The
supernates were placed into individual 1 ml capped tubes, labeled, and stored at -80ْC
until time of use. Plates containing MCF-7 cells were seeded at concentration of 8 x 104
cells per well, incubated at 37ْC and 5% CO2, and supernates were collected for 4
consecutive days. Supernates for the second VEGF assay were collected in the same
manner; however, based upon review of data from the first VEGF assay, the HT-29 cell
line was seeded at 5 x 104 cells per well and the MCF-7 cell line was seeded at 8 x 104
cells per well. Collected supernates were placed into individual 1 ml capped tubes,
labeled, and stored at -80ْC until time of use. Supernate from HT-29 cells and MCF-7
cells that underwent no treatment was used as a positive control and supernate from

36

LM929 cells was used as a negative control. Compound RS242 was not used in the
second VEGF assay as the supply had run out.
Prior to the start of the VEGF assay, all reagents and working standards were
prepared via instructions provided in the kit (see Appendix 1). The 1 mL tubes
containing cell supernates treated with the different ruthenium-based compounds were
removed from storage and thawed in a water bath. The 96-well plate was removed from
its foil pouch and placed in the hood. 50 µL Assay Diluent RD1W was placed in each
well. 200 µL of the Standard, control, or previously collected cell supernate was added
to each well. The 96-well plate was covered with the adhesive strip provided in the assay
kit and incubated for 2 hours at room temperature to allow any VEGF present in the
standard, control, or cell supernate to bind to the immobile VEGF-specific monoclonal
antibody, which came precoated on the 96-well plate. Each well was aspirated and
washed with 400 µL Wash Buffer a total of three times to wash away any substances that
were not bound to the immobile antibody. Complete removal of liquid from all wells
during each wash was necessary for good test results. After the final wash, any
remaining Wash Buffer was removed by inverting the plate and blotting it against a clean
paper towel. Next, 200 µL of VEGF Conjugate was placed in each well. The VEGF
Conjugate is an enzyme-linked polyclonal antibody that is specific for VEGF. The
VEGF Conjugate will bind to the VEGF that is bound from the standard, control, or cell
supernate in the above step. All wells were covered with a new adhesive strip and the
plate was incubated for 2 hours at room temperature to allow the VEGF Conjugate time
to bind to the VEGF present on the plate. Each well was aspirated and washed using the
above procedure. 200 µL of Substrate Solution was then placed in each well. The
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reaction of the Substrate Solution and the antibody-enzyme reagent yields a colored
product. Once the Substrate Solution was added, the plate was protected from light by
foil and incubated for 20 minutes at room temperature to allow time for the color to
develop. Lastly, 50 µL of Stop Solution was placed in each well to stop the color
development. The optical density of each well was taken at 450 nm on a Cary 50
microplate reader (Varian, Palo Alto, California) as the color develops in proportion to
the amount of VEGF bound from the substrate, control, or cell supernate. Readings were
also taken at 540 nm and a wavelength correction was made by subtracting the readings
at 450 nm from the readings at 540 nm. The wavelength subtraction is necessary to
correct for optical imperfections in the plate.
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CHAPTER 3
RESULTS
MTT Assays
Data were pooled from five MTT assays from which the 6 ruthenium compounds
were tested on the HT-29 cell line (Table 2). The lower the optical density (O.D.)
reading, the higher the level of cell growth inhibition. A one-way ANOVA was then
performed for each compound to test whether or not the means of each ruthenium
compound at the highest concentration showed a significant difference from the mean of
cells that underwent no treatment.
Table 2
HT-29 Mean Absorbance Values
Compound

Solution

O.D.590 nm*

Cell Only

NA

1.6756

NG2

Saturated**

0.2901

QL19

Saturated**

1.4559

RS216

Saturated**

1.2694

RS244

Saturated**

0.3131

RS247

Saturated**

1.6008

RS250

Saturated**

0.9112

* Mean absorbance values of 5 MTT assays
** Saturation as defined in Materials and Methods

Data were also pooled from five MTT Assays for each compound tested on the
MCF-7 cell line (Table 3) and a one-way ANOVA was performed to see whether or not
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the means from cells treated with the individual compounds varied significantly from the
mean of cells that underwent no treatment. The results of the one-way ANOVA for both
cell lines are shown in Table 4. The data from all cells tested with the compound RS242
were discarded as the solvent used with the compound, DMSO, caused cell death. This
made it impossible to determine if any cell death was related to the compound itself.
Table 3
MCF-7 Mean Absorbance Values
Compound

Solution

O.D.590 nm*

Cell Only

NA

1.7238

NG2

Saturated**

0.4654

QL19

Saturated**

1.585

RS216

Saturated**

1.3534

RS244

Saturated**

0.8768

RS247

Saturated**

1.5268

RS250

Saturated**

1.5039

* Mean absorbance values of 5 MTT assays
** Saturation as defined in Materials and Methods
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Table 4
Results of the one-way ANOVA for the HT-29 and MCF-7 cell lines
Cancer Cell Line

Compound

Significance

HT-29

NG2

HT-29

RS250

MCF-7

NG2

F = 26.45,
P < 0.0001
F = 13.37,
P < 0.001
F = 56.62,
P < 0.001

Difference between the means of cells treated with ruthenium compounds NG2 and RS250 and the mean of
cells that underwent no treatment

A one-way ANOVA is a statistical test to determine whether or not the means of
two or more populations are significantly different (Keller, 2005). A significant
ANOVA, meaning the p-value is below the level of significance, usually .05, allows for
the null hypothesis to be rejected. The p-value is a quantitative measurement of the
evidence that does not support the null hypothesis.
While none of the 7 ruthenium-based compounds tested was responsible for
causing cell death in either cell line, 2 of the 7 ruthenium-based compounds tested on the
HT-29 cell line caused inhibition of cell growth at the highest concentration of the
compounds tested in vitro. Compounds NG2 and RS250 were responsible for causing
cell growth inhibition in the HT-29 cell line (Table 5).
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Table 5
Percent Inhibition in HT-29 cell line
Compound

Solution

Percent Inhibition

NG2

Saturated*

82.7 %

RS250

Saturated*

45.62 %

*Saturation as defined in Materials and Methods.

In the MCF-7 cell line compound NG2 showed a 73.01% inhibition of cell growth
at the highest concentration tested in vitro, which is a saturated level. Saturation is
defined in Materials and Methods.
VEGF Assays
Results of the first VEGF assay indicated that in the HT-29 cell line, cells seeded
at 5 x 104 cells per well produced the most VEGF. As indicated in the literature, the first
VEGF assay confirmed results that MCF-7 cells seeded at 8 x 104 cells per well produced
a high amount of VEGF. Supernate from each cell line that underwent no treatment was
used as a positive control, while the noncancerous cell line, LM929, was used as a
negative control as it is not known to make VEGF. Results of the first VEGF assay for
the HT-29 cell line are shown in Table 6. Results of the first VEGF assay for the MCF-7
cell line are shown in Table 7. The lower the optical density (O.D.) reading, the higher
the level of cell growth inhibition.

42

Table 6
Results of first VEGF/HT-29 assay
Cell Line

Cell Concentration

O.D.450nm*

HT-29

5 x 103

0.457

HT-29

1 x 104

1.059

HT-29

5 x 104

3.742

HT-29

8 x 104

3.077

HT-29

2 x 105

2.218

Cell Line

Cell Concentration

O.D.450nm

MCF-7

8 x 104

3.247

MCF-7

8 x 104

3.490

* Mean absorbance of two assays

Table 7
Results of first VEGF/MCF-7 assay

* Mean absorbance of two assays

Once the highest level of VEGF produced in both cell lines was confirmed, a
second VEGF assay was run in the same manner as the first; however, all HT-29 cells
were seeded at 5 x 104 cells per well and all MCF-7 cells were seeded at 8 x 104 cells per
well. The results of the second VEGF assay for the HT-29 and MCF-7 cell lines are
shown in Figure 2 and Figure 3, respectively.
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Figure 2. Results of second VEGF/HT-29 assay.
MCF-7 VEGF Data
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Figure 3. Results of second VEGF/MCF-7 assay.
Data from the second VEGF assay were used in a two-way ANOVA with
replication to determine if there was a statistical difference between cells treated with

44

individual ruthenium compounds within the separate cancer cell lines. An individual
two-way ANOVA with replication was run using the data from Day 1, 2, 3, and 4, to
determine whether or not there was a significant decrease in VEGF production after
treatment of cells with the individual ruthenium compounds. Each cancer cell line was
tested separately.
A two-way ANOVA is used when there is one measurement variable present and
two nominal variables, or factors, used in an experiment. In this experiment, we are
testing the hypothesis that the ruthenium compounds have an effect on the human cancer
cell lines. The amount of VEGF was measured in cells treated with the various
ruthenium compounds as well as cells that underwent no treatment. The two nominal
variables are the various ruthenium compounds and the two different human cancer cell
lines. The two-way ANOVA with replication was used because there were multiple
observations made in the assay (Coolidge, 2000).
When determining levels of significance, the two-way ANOVA with replication
compares several important things. First, the two-way ANOVA with replication looks
for a significant difference in sets of data or columns. A column (set of data) is defined
as each ruthenium compound separately tested on one human cancer cell line. The twoway ANOVA with replication compares columns and determines whether there is a
significant p-value in one cancer cell line treated with different ruthenium compounds.
The two-way ANOVA with replication also looks for a significant difference between
samples. A sample is defined as the sets of data for each human cancer cell line used.
For this study we have two samples, the MCF-7 and HT-29 human cancer cell lines. The
two-way ANOVA with replication also determines whether the ruthenium compounds
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and individual cell lines had an effect on one another. This is known as the interaction
variable.
The results of the two-way ANOVA with replication are shown in Table 8. Data
on Day 4 could not be evaluated as the readings from the VEGF assay were regarded as
inaccurate because the VEGF readings were too high to be accurately measured against
the VEGF standard curve.
Table 8
Results of two-way ANOVA with replication
Treatment w/

Difference Between

Ruthenium

Cell Lines

Interaction Variable

Compounds
Significance on Day

F =188.08,

X

X

1

P < 0.0001

Significance on Day

F =189.06,

F = 196.45,

F = 46.43,

2

P < 0.0001

P < 0.0001

P < 0.0001

Significance on Day

F = 16.54,

F = 123.28,

F = 12.37,

3

P < 0.0001

P < 0.0001

P < 0.0001

Significance on Day

NA

NA

NA

4

46

Although the two-way ANOVA with replication allows for determination of
significance to be made, it does not give indication as to which factor is responsible.
Upon finding that the interaction variable was significant, a multiple comparisons test
was used on the individual cell line data to further determine which ruthenium
compound(s) showed significant VEGF reduction.
Multiple comparison tests, also referred to as a posteriori tests or post hoc tests,
are commonly used after a significant ANOVA in which the null hypothesis has been
rejected (Coolidge, 2000). Multiple comparison tests aid in finding a pattern of
significant differences among the means and maintain the Type 1 Error rate at an
acceptable level (p = .05 or less) while looking at the Least Significant Difference (LSD)
and the omega squared (ω2). The Least Significant Difference is a test that does a pairwise comparison of the means of cells treated with the various ruthenium compounds
(Coolidge). The Least Significant Difference is determined by this comparison. Based
on the sample size a value is determined. The determined value is a benchmark value of
significance. For a mean to be considered significant, the difference must be greater than
the benchmark value. A Tukey’s multiple comparison test was also done to determine
the ω. A Tukey’s multiple comparison test is a method similar to the LSD test for finding
a benchmark value of significance. The Tukey’s test is considered more conservative
than a LSD test for lowering the Type 1 Error rate and is used to reaffirm the
significance. If the ω α is greater than the benchmark value, then the mean is considered
significant. In the Tukey’s multiple comparison test, the ω2 value represents the
magnitude of the effect of the independent variable upon the dependent variable. Table 9
shows the values by which the magnitude of effect is determined.
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Table 9
Values for ω2 that determine magnitude of effect
ω2 > .15

Large Effect

ω2 > .06

Medium Effect

ω2 > .01

Small Effect

If the absolute value of the difference is greater than the LSD α and the Omega α, then
the two tests are in agreement that the treatment means are significant.
On Day 1, the results of the multiple comparison tests in the HT-29 cell line
revealed a significant difference between the mean of cells treated with compounds NG2,
QL19, RS216, RS247, and RS250 compared with the mean of the cells that underwent no
treatment. The most significant difference was found between cells that underwent no
treatment and cells that were treated with RS250. Cells treated with compounds QL19,
RS247, RS216, and NG2, showed a decreasing significance, respectively (Table 10).
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Table 10
HT-29 Multiple Comparison Test Results - Day 1
Treatment

Difference

NG2

-2.73625

QL19

-3.1423

RS216

-2.81095

RS247

-3.0685

RS250

-3.73155

The difference refers to the optical density of the cells treated with individual ruthenium compounds as
compared with the optical density of the cell supernate for cells that underwent no treatment. LSD α =
0.041343368, where p = 0.05; Omega α = 0.067263679, where p = 0.05.

On Day 1, the results of the multiple comparison tests in the MCF-7 cell line
revealed a significant difference between the mean of cells treated with compounds NG2,
QL19, RS216, RS247, and RS250 compared with the mean of cells that underwent no
treatment. The most significant difference between cells treated with compounds and
cells that underwent no treatment was found in cells treated with QL19, followed by
RS250, NG2, RS247, and RS216, respectively (Table 11).

49

Table 11
MCF-7 Multiple Comparison Test Results - Day 1
Treatment

Difference

NG2

-2.6109

QL19

-2.990375

RS216

-2.50415

RS247

-2.54415

RS250

-2.6248

The difference refers to the optical density of the cells treated with individual ruthenium compounds as
compared with the optical density of the cell supernate for cells that underwent no treatment. LSD α =
0.600629911, where p = 0.05; Omega α = 0.977196089, where p = 0.05.

On Day 2, the results of the multiple comparison tests in the HT-29 cell line
revealed a significant difference between the mean of cells treated with compounds NG2,
QL19, RS216, RS247, and RS250 compared with the mean of cells that underwent no
treatment. The most significant difference between cells treated with compounds and
cells that underwent no treatment was found in cells treated with RS250, followed by
RS247, QL19, NG2, and RS216, respectively (Table 12).
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Table 12
HT-29 Multiple Comparison Test Results - Day 2
Treatment

Difference

NG2

-1.357

QL19

-1.5505

RS216

-1.1635

RS247

-1.7246

RS250

-3.40605

The difference refers to the optical density of the cells treated with individual ruthenium compounds as
compared with the optical density of the cell supernate for cells that underwent no treatment. LSD α =
0.331967951, where p = 0.05; Omega α = 0.540095952, where p = 0.05.

On Day 2, the results of the multiple comparison tests in the MCF-7 cell line
revealed a significant difference between the mean of cells treated with compounds NG2,
QL19, RS216, RS247, and RS250 compared with the mean of cells that underwent no
treatment. The most significant difference between cells treated with compounds and
cells that underwent no treatment was found in cells treated with RS247, followed by
NG2, QL19, RS250, and RS216, respectively (Table 13).
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Table 13
MCF-7 Multiple Comparison Test Results - Day 2

Treatment

Difference

NG2

-2.0838

QL19

-1.83385

RS216

-1.76235

RS247

-2.30425

RS250

-1.82615

The difference refers to the optical density of the cells treated with individual ruthenium compounds as
compared with the optical density of the cell supernate for cells that underwent no treatment. LSD α =
0.287341626, where p = 0.05; Omega α = 0.467491058, where p = 0.05.

On Day 3, the results of the multiple comparison tests in the HT-29 cell line
revealed a significant difference between the mean of cells treated with compounds NG2,
QL19, RS216, RS247, and RS250 compared with the mean of cells that underwent no
treatment. The most significant difference between cells treated with compounds and
cells that underwent no treatment was found in cells treated with NG2, followed by
RS247, RS216, and RS250, respectively (Table 14). Data obtained from cells treated
with compound QL19 on Day 3 were determined to be inaccurate as the readings were
too high to be considered accurate when compared against the VEGF standard curve, and
thus was removed.
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Table 14
HT-29 Multiple Comparison Test Results - Day 3
Treatment

Difference

NG2

-0.8857

RS216

-0.00095

RS247

-0.2467

RS250

-0.01565

The difference refers to the optical density of the cells treated with individual ruthenium compounds as
compared with the optical density of the cell supernate for cells that underwent no treatment. LSD α =
0.499455614, where p = 0.05; Omega α = 0.778994231, where p = 0.05.

On Day 3, the results of the multiple comparison tests in the MCF-7 cell line
revealed a significant difference between the mean of cells treated with compounds NG2,
QL19, RS216, RS247, and RS250 compared with the mean of cells that underwent no
treatment. The most significant difference between cells treated with compounds and
cells that underwent no treatment was found in cells treated with RS250, followed by
RS216, RS247, QL19, and NG2, respectively (Table 15).
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Table 15
MCF-7 Multiple Comparison Test Results - Day 3
Treatment

Difference

NG2

-0.74375

QL19

-0.77145

RS216

-0.89865

RS247

-0.78445

RS250

-0.94475

The difference refers to the optical density of the cells treated with individual ruthenium compounds as
compared with the optical density of the cell supernate for cells that underwent no treatment. LSD α =
0.464371289, where p = 0.05; Omega α = 0.755509839, where p = 0.05.

On Day 4, the results of the multiple comparison tests in the HT-29 cell line
revealed a significant difference between the mean of cells treated with compounds NG2,
QL19, RS216, RS247, and RS250 compared with the mean of cells that underwent no
treatment. The most significant difference between cells treated with compounds and
cells that underwent no treatment was found in cells treated with RS247 followed by cells
treated with RS250 (Table 16). Data obtained from cells treated with compounds NG2,
QL19, and RS216 on Day 4 were determined to be inaccurate because the readings were
too high to be considered accurate when compared against the VEGF standard curve, thus
the results were removed.

54

Table 16
HT-29 Multiple Comparison Test Results - Day 4
Treatment

Difference

RS247

-0.2467

RS250

-0.01565

The difference refers to the optical density of the cells treated with individual ruthenium compounds as
compared with the optical density of the cell supernate for cells that underwent no treatment. LSD α =
0.344898349, where p = 0.05; Omega α = 0.452899764, where p = 0.05.

On Day 4, the results of the multiple comparison tests in the MCF-7 cell line
revealed a significant difference between the mean of cells treated with compounds NG2,
QL19, RS216, RS247, and RS250 compared with the mean of cells that underwent no
treatment. The most significant difference between cells treated with compounds and
cells that underwent no treatment was found in cells treated with RS216, followed by
RS250, RS247, NG2, and QL19, respectively (Table 17).
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Table 17
MCF-7 Multiple Comparison Test Results - Day 4
Treatment

Difference

NG2

-0.28565

QL19

-0.2219

RS216

-0.7655

RS247

-0.545

RS250

-0.6054

The difference refers to the optical density of the cells treated with individual ruthenium compounds as
compared with the optical density of the cell supernate for cells that underwent no treatment. LSD α =
0.292483749, where p = 0.05; Omega α = 0.475857047, where p = 0.05.
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CHAPTER 4
DISCUSSION
The most commonly used chemotherapeutic drugs are platinum(II) compounds
(National Cancer Institute, 2007). Cisplatin is the most commonly used platinum based
compound in chemotherapy. Due to the problems that have been encountered with many
of the currently used platinum based compounds such as developed drug resistance by the
tumor cells, toxic effects of the compounds on healthy tissue, inadequate tissue targeting,
and impaired transport-uptake of the compounds by the tumor cells, a great effort has
been made to find new metals to substitute in place of platinum (Anderson et al., 2007).
Ruthenium is a rare transition metal of the platinum group. The two key
characteristics of ruthenium(III) complexes are their exceptional antimetastatic behavior
and the exhibition of antitumor activity. Of the ruthenium complexes tested, NAMI-A
has shown the most promise as an anticancer agent because it inhibits metastasis
formation and growth while being devoid of severe cytotoxic effects to healthy cells.
Also, it does not appear to modify cell growth in healthy tissue (Ravera et al., 2004). Our
findings are consistent with this.
Out of the 7 ruthenium compounds tested on the HT-29 and MCF-7 cell lines, our
data indicates that compounds NG2 and RS250 exhibit antitumor activity as they
inhibited cell growth in the HT-29 colon cancer cell line. Compound NG2 also appears
to exhibit antitumor activity as it inhibited cell growth in the MCF-7 breast cancer cell
line. These are promising results as breast cancer and colon cancer are not treatable with
cisplatin. More testing will need to be done to determine whether or not compounds NG2
and RS250 are devoid of toxic effects to healthy cells. Future tests can also be run to
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determine the mechanism by which our ruthenium compounds bind to DNA causing an
interruption in the cell cycle, thus inhibiting cell growth in the cancer cells. We know
that DNA is the primary binding site of the compounds. However, the mode of
association between the ruthenium compounds and DNA is unknown and needs to be
distinguished between external binding, groove binding, and intercalation (Miller et al.,
1985).
The mechanism by which ruthenium compounds NG2 and RS250 inhibit cell
growth is yet to be determined, but it is known that ruthenium(III) complexes are more
inactive than their analogous ruthenium(II) derivatives. An “activation by reduction”
mechanism has been suggested in order to explain the biological activity of all chloroamino ruthenium derivatives (Ravera et al., 2004). Because the amount of oxygen is less
and the pH is lower at tumor sites, the “activation by reduction” mechanism of ruthenium
causes it to be extremely selective as the metal complexes may aggregate in the oxygenlacking environment (Anderson et al., 2007). Once the “activation by reduction” has
taken place in a ruthenium(III) complex, or hydrolysis of at least one chloride has
occurred, the complex has the capability to bind to DNA or transferrin (Alessio et al.,
2000). Because of the large number of transferring receptors located on the cell surface
of cancer cells, it is thought that ruthenium complexes are taken up into the cell via this
method.
Although direct toxicity to the tumor itself is a key factor of a chemotherapeutic
drug, antimetastatic properties are equally as important. The major cause of a poor
clinical outcome in cancer patients is the progression of tumors from a benign state with
limited growth to an invasive state with tumor metastasis (Sava et al., 2004). Ruthenium
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compounds NG2 and RS250 need to be tested to determine if they work by causing
transient cell cycle arrest of tumor cells in the premitotic G2/M phase, as does NAMI-A
(Bergamo et al., 1998). It is hypothesized that NAMI-A shows transient cell cycle arrest
of tumor cells in the premitotic G2/M phase by tying up the DNA so that the DNA cannot
replicate (Sava et al., 2003). Compounds NG2 and RS250 might use this mechanism of
action as they are similar in properties to NAMI-A.
Tumor growth and metastasis survival are strongly dependent on nourishment
provided by the bloodstream. Because cancer cells multiply very rapidly, they require a
high blood flow to provide nutrients for this cell division. Tumors ensure this continual
blood supply by forming new capillaries from preexisting blood vessels, a process known
as angiogenesis (Quantikine Human VEGF Immunoassay, 2006). Angiogenesis is
regulated by vascular endothelial growth factor (VEGF). VEGF production is
significantly increased in most cancer cell lines thus ensuring a continuous blood supply
to the cancer cells (Ferrara et al., 1999).
Five of the 7 ruthenium compounds were tested to see if VEGF production had
decreased in the cells treated with the various compounds. If the VEGF level had
decreased, it would be an indication that the ruthenium-based compounds had interfered
with VEGF production at some level. The ruthenium compounds were further examined
to determine whether the level of VEGF production was decreased. This would have
little effect on cells grown in the lab because the cells are well fed by the growth medium
and would have no need to make VEGF; however, this would be very important to cancer
cells growing in vivo. Cancer cells grown in vivo rely on VEGF to produce blood vessels
from preexisting blood vessels in order that the necessary nutrients be obtained by the
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cancer cells, resulting in optimal cell growth (Ferrara et al., 1999). Thus, the ruthenium
compounds that can decrease the amount of VEGF produced by the cancer cell lines in
vitro are of interest because they may be able to cause cell growth inhibition in vivo by
effectively reducing VEGF production to levels too low to nutritionally sustain human
cancer cells.
We were able to initially reject our null hypothesis that the ruthenium compounds
would not interfere with the cell’s ability to produce VEGF. In the HT-29 cell line, cells
treated with compound RS250 exhibited the highest inhibition of VEGF production on
Day 1 and Day 2. In the MCF-7 cell line, cells treated with QL19 appeared to produce
the least amount of VEGF on Day 1, followed closely by cells treated with compound
RS250. On Day 2, cells treated with RS250 appeared to produce less VEGF than cells
treated with compound QL19; however, while both compounds appeared to inhibit VEGF
production in the cell line above, it was not in a truly significant manner from cells
treated with the other ruthenium compounds. By Day 4, VEGF production did not appear
to be inhibited in either human cancer cell line. This would indicate that while the
ruthenium compounds were able to inhibit VEGF production initially, the amount of
VEGF produced during that time was still great enough to sustain the cancer cells. More
research needs to be done to determine why the cancer cells treated with compounds
RS250 and QL19 were initially inhibited. One possibility is that the cancer cells that
were seeded on Day 1 took up all of the ruthenium compound and VEGF production was
inhibited. However, once the cells divided, the new cells were able to make enough
VEGF to allow the cells to flourish. Another possibility is that the cells initially seeded
took up most of the ruthenium compound. Once those cancer cells divided, the daughter
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cells took up the remaining compound. In either scenario, once the cancer cells had
divided multiple times, enough VEGF was produced to sustain the cell line.
Although the mechanism of action is not known as to how the ruthenium
compounds acted upon the cancer cell lines to cause inhibition of VEGF production,
there are several factors known to regulate VEGF production. Hypoxia inducible factor
(HIF-1) plays a major role in angiogenesis and tumor growth. HIF-1 is a heterodimeric
transcription factor composed of HIF-1α and HIF-1β subunits (Pellizzaro et al., 2002). In
vivo, the inhibition of HIF-1α leads to the reduced tumor size while the expression of
HIF-1α causes a growth in tumor size (Pellizzaro et al.).
Using two different shRNA expression vectors, expression of VEGF was
inhibited in a line of colorectal adenocarcinoma cells, HT-29, by reducing the
transcription levels of VEGF mRNA, which reduced VEGF protein levels (Li et al.,
2007). Our ruthenium compounds could target RNA and interfere with a gene used in
VEGF production.
While there are multiple isoforms of VEGF, VEGF-A is a positive regulator for
angiogenesis. It primarily binds two high affinity receptor tyrosine kinases (RTKs),
VEGFR-1 (Flt-1), and VEGFR-2 (Flt-1/KDR). The ruthenium compounds may be acting
as RTK inhibitors by blocking the receptor sites, thus inhibiting the binding of VEGF to
the receptor site. More research will need to be done to determine the method by which
our ruthenium compounds are inhibiting VEGF production in both cancer cell lines.
The overall hypothesis for the first experiment was that ruthenium compounds
would have a cytotoxic effect on human carcinomas. More specifically, we hypothesized
that the ruthenium compounds would have a cytotoxic effect on human breast carcinoma
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and human colon adenocarcinoma, while our null hypothesis was that the ruthenium
compounds would have no effect on the two cancer cell lines we worked with. While
none of the compounds tested had a complete cytotoxic effect on either of the cell lines,
compounds NG2 and RS250 caused inhibition of cell growth in the HT-29 cell line and
compound NG2 caused inhibition of cell growth in the MCF-7 cell line.
The overall hypothesis for the second experiment was that the various ruthenium
compounds would interfere with the cell’s ability to produce VEGF. More specifically,
we hypothesized that the ruthenium compounds would interfere with cell’s ability to
produce VEGF in the human breast carcinoma and human colon adenocarcinoma cell
lines, while our null hypothesis was that the ruthenium compounds would not interfere
with the cell’s ability to produce VEGF in either human cancer cell line. In the HT-29
cell line, compound RS250 did interfere with the cell’s ability to produce VEGF. In the
MCF-7 cell line, compounds QL19 and RS250 appeared to inhibit VEGF production as
well. Therefore, initially our null hypothesis can be rejected on Days 1-3 in both cell
lines, but not rejected on Day 4 as inhibition of VEGF production was not observed.
Future Research
Two of the ruthenium-based compounds, NG2 and RS250, appear to have an
inhibitory effect on cell growth in the HT-29 cell line, while one ruthenium-based
compound, NG2, appears to have an inhibitory effect on cell growth in the MCF-7 cell
line. The antitumor properties of these ruthenium compounds need to be further tested to
determine how they might be employed in the future. Compounds NG2 and RS250 will
need to be characterized to determine whether or not they are devoid of toxic effects on
healthy tissue. Compound NG2 exhibited inhibition of VEGF production on Day 1 in the
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HT-29 cell line, while compounds QL19 and RS250 exhibited inhibition of VEGF
production on Day 1 in the MCF-7 cell line. Compound RS250 was the only compound
tested to cause cell growth inhibition and inhibition of VEGF production in the HT-29
cell line. A possible explanation for the inhibition of cell growth in HT-29 cells treated
with compound RS250 is that the VEGF production was inhibited enough to cause cell
growth inhibition but not enough to cause cell death. Further testing needs to be done to
determine the mechanism of action for compound RS250. It is our hope that one day
these compounds might be effectively used in cancer treatment.
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APPENDIX
Reagent Preparation in VEGF Assay
Bring all reagents to room temperature before use.
Wash Buffer - If crystals have formed in concentrate, warm to room temperature and
mix gently until the crystals have completely dissolved. Dilute 20 mL of Wash Buffer
Concentrate into deionized or distilled water to prepare 500 mL of Wash Buffer.
Substrate Solution – Color Reagents A and B should be mixed together in equal
volumes within 15 minutes of use. Protect from light. 200 µL of the resultant mixture is
required per well.
VEGF Standard – Reconstitute the VEGF Standard with 1.0 mL of Calibrator Diluent
RD5K (for cell culture supernate samples) or Calibrator Diluent RD6@ (for
serum/plasma samples). This reconstitution produces a stock solution of 2000 pg/mL.
Allow the standard to sit for a minimum of 15 minutes with gentle agitation prior to
making dilutions.
For Cell Culture Supernate Samples: Use polypropylene tubes. Pipette 500 µL of
Calibrator Diluent RD5K into each tube. Use the stock solution to produce a dilution
series (below). Mix each tube thoroughly before the next transfer. The 1000 pg/mL
dilution serves as the high standard. Calibrator Diluent RD5K serves as the zero standard
(0 pg/mL).
For Serum/Plasma Samples: Use polypropylene tubes. Pipette 500 µL of Calibrator
Diluent RD6U into each tube. Use the stock solution to produce a dilution series
(below). Mix each tube thoroughly before the next transfer. The undiluted standard
serves as the high standard (2000 pg/mL). Calibrator Diluent RD6U serves as the zero
standard (0 pg/mL).
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